Guidelines from the ASCO and OH Joint Expert Group recommend pembrolizumab for non-squamous cell carcinoma (non-SCC) with high PD-L1 expression (Tumor Proportion Score [TPS]≥50%) (41). Here, CD274 is linked to neoplasm.